A single laboratory testing session at the beginning of the season might be sufficient to adequately prescribe training loads based on HR data in elite endurance athletes such as professional cyclists. This would simplify the testing schedule generally used for this type of athlete.
Professional road cycling is an extreme endurance sport. Approximately 30000 to 35000 km are cycled each year in training and competition and some races, such as the Tour de France last 21 days (approximately 100 hours of competition) during which professional cyclists (PC) must cover >3500 km. In some phases of such a demanding sport, on the other hand, exercise intensity is surprisingly high, since PC must complete prolonged periods of exercise (i.e. time trials, high mountain ascents) at high percentages (approximately 90%) of maximal oxygen uptake (VO2max) [above the anaerobic threshold (AT)]. Although numerous studies have analysed the physiological responses of elite, amateur level road cyclists during the last 2 decades, their findings might not be directly extrapolated to professional cycling. Several studies have recently shown that PC exhibit some remarkable physiological responses and adaptations such as: an efficient respiratory system (i.e. lack of 'tachypnoeic shift' at high exercise intensities); a considerable reliance on fat metabolism even at high power outputs; or several neuromuscular adaptations (i.e. a great resistance to fatigue of slow motor units). This article extensively reviews the different responses and adaptations (cardiopulmonary system, metabolism, neuromuscular factors or endocrine system) to this sport. A special emphasis is placed on the evaluation of performance both in the laboratory (i.e. the controversial Conconi test, distinction between climbing and time trial ability, etc.) and during actual competitions such as the Tour de France.
The physiological loads imposed on cyclists' bodies do not differ between the Tour and Vuelta, despite the longer duration of daily stages in the former race.
During both F and TT, professional riders spontaneously adopt higher cadences (around 90 rpm) than those previously reported in the majority of laboratory studies as being the most economical. In contrast, during HM they seem to adopt a more economical pedalling rate (approximately 70 rpm), possibly as a result of the specific demands of this competition phase.
The Z-disk protein alpha-actinin-3 is only expressed in type II muscle fibres, which are responsible for generating forceful contractions at high velocity. Despite the evolutionary conservation of alpha-actinin-3, approximately one in every five Caucasians of European ancestry is totally deficient in this protein, due to homozygosity for a R577X polymorphism in the ACTN3 gene. This, together with the results of recent research on elite athletes, suggests that the "null" XX polymorphism might confer some advantage to endurance performance events. To test this hypothesis, we studied the frequency distribution of R577X genotypes in a group of 50 top-level male professional cyclists (26.9 +/- 0.4 yrs [mean +/- SEM]; VO2max: 73.5 +/- 0.8 ml x kg (-1) x min (-1)). Their results were compared with those of a group of 52 Olympic-class male endurance runners (26.8 +/- 0.6 yrs; VO2max: 73.3 +/- 0.8 ml x kg (-1) x min (-1)) and 123 healthy, sedentary male controls. All subjects were Caucasian, and of European ancestry. No significant differences (p > 0.05) were found between groups: RR: 28.5 %; RX: 53.6 % and XX: 17.9 % in controls; RR: 28.0 %; RX: 46.0 % and XX: 26.0 % in cyclists; and RR: 25.0 %; RX: 57.7 %; XX: 17.3 % in runners). No differences were found in indices of endurance performance (VO2peak or ventilatory thresholds) between athlete carriers of each R577X genotype. In summary, although the alpha-actinin-3 deficient XX genotype may be detrimental for sprint performance in humans, the R577X polymorphism of the ACTN3 gene does not appear to confer an advantage on the ability of male athletes to sustain extreme endurance performance.
Objectives-To analyse the slow component of oxygen uptake (Ṽ O 2 ) in professional cyclists and to determine whether this phenomenon is due to altered neuromuscular activity, as assessed by surface electromyography (EMG).
Methods-The
We aimed to determine the frequency of the VO2max plateau phenomenon in top-level male professional road cyclists (n = 38; VO2max [mean +/- SD]: 73.5 +/- 5.5 ml.kg(-1).min(-1)) and in healthy, sedentary male controls (n = 37; VO2max: 42.7 +/- 5.6 ml.kg(-1).min(-1)). All subjects performed a continuous incremental cycle-ergometer test of 1-min workloads until exhaustion. Power output was increased from a starting value of 25 W (cyclists) or 20 W (controls) at the rate of 25 W.min(-1) (cyclists) or 20 W.min(-1) (controls) until volitional exhaustion. We measured gas-exchange and heart rate (HR) throughout the test. Blood concentrations of lactate (BLa) were measured at end-exercise in both groups. We defined maximal exercise exertion as the attainment of a respiratory exchange rate (RER) >or= 1.1; HR > 95 % age-predicted maximum; and BLa > 8 mmo.l(-1). The VO2max plateau phenomenon was defined as an increase in two or more consecutive 1-min mean VO2 values of less than 1.5 ml.kg(-1).min(-1). Most cyclists met our criteria for maximal exercise effort (RER > 1.1, 100 %; 95 % predicted maximal HR [HRmax], 82 %; BLa > 8 mmol.l(-1), 84 %). However, the proportion of cyclists attaining a V.O (2max) plateau was considerably lower, i.e., 47 %. The majority of controls met the criteria for maximal exercise effort (RER > 1.1, 100 %; predicted HRmax, 68 %; BLa > 8 mmol. l(-1), 73 %), but the proportion of these subjects with a VO2max plateau was only 24 % (significantly lower proportion than in cyclists [p < 0.05]). Scientists should consider 1) if typical criteria of attainment of maximal effort are sufficiently stringent, especially in elite endurance athletes; and 2) whether those humans exhibiting the VO2max plateau phenomenon are those who perform an absolute maximum effort or there are additional distinctive features associated with this phenomenon.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.